Targeting the Nrf2-SIRT1 axis abrogates metabolic plasticity and sensitizes breast cancer to oxidative stress
Apoptosis · 2026-12 · 31 (12)
DOI: 10.1007/s10495-026-02471-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, online erschienen am 11.11.2026. Verfasst von Chen-Chun Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 1-1, Jen-Ai Road, Taipei, 10051, Taiwan. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Oxidative Stress, Sirtuin 1, Breast Neoplasms. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
BACKGROUND: Hyperactivation of the antioxidant transcription factor Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) strongly correlates with tumor progression and poor prognosis in aggressive breast cancers. While Nrf2 is known to influence tumor metabolism, the precise molecular mechanism by which it orchestrates "metabolic plasticity", the ability to flexibly fulfill immense bioenergetic demands, remains largely elusive. METHODS AND RESULTS: Integrating clinical dataset analysis with in vitro genetic manipulation (MCF7 and MDA-MB-231), we confirmed Nrf2 as a core driver of breast cancer tumorigenesis. Metabolic profiling revealed that Nrf2 confers robust metabolic plasticity by concurrently upregulating both oxidative phosphorylation (OXPHOS) and glycolysis, resulting in an ATP production surge. Mechanistically, Nrf2 upregulates the expression of SIRT1, which serves as an indispensable hub for this dual metabolic enhancement. Pharmacological inhibition (using NAM or EX527) or genetic knockdown of SIRT1 effectively dismantled the Nrf2-driven metabolic advantage, drastically reducing ATP levels and suppressing colony formation. Furthermore, we uncovered an additive cytotoxic effect where combining SIRT1 inhibition with oxidative stress (H2O2) severely impaired the bioenergetic reserve and disrupted redox balance, leading to a marked suppression of cancer cell survival and clonogenic capacity. CONCLUSION: Our findings identify the Nrf2-SIRT1 axis as a master coordinator of metabolic plasticity in breast cancer. Repurposing SIRT1 inhibitors to disrupt this bioenergetic adaptation provides a potential, mechanism-guided rationale to sensitize therapy-resistant and Nrf2-hyperactivated breast cancer cells to oxidative stress in preclinical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 1-1, Jen-Ai Road, Taipei, 10051, Taiwan.
- Heart Center, Cheng-Hsin General Hospital, Taipei, Taiwan.
- Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, 1-1, Jen-Ai Road, Taipei, 10051, Taiwan. hnkung@ntu.edu.tw.
Förderung
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Liu, C. C., Lu, K. H., Syu, J. P., & Kung, H. N. (2026). Targeting the Nrf2-SIRT1 axis abrogates metabolic plasticity and sensitizes breast cancer to oxidative stress. Apoptosis, 31(12). https://doi.org/10.1007/s10495-026-02471-3
Vancouver
Liu CC, Lu KH, Syu JP, Kung HN. Targeting the Nrf2-SIRT1 axis abrogates metabolic plasticity and sensitizes breast cancer to oxidative stress. Apoptosis. 2026;31(12). doi:10.1007/s10495-026-02471-3
BibTeX
@article{Liu2026,
author = {Liu, Chen-Chun and Lu, Kai-Hsi and Syu, Jhih-Pu and Kung, Hsiu-Ni},
title = {Targeting the Nrf2-SIRT1 axis abrogates metabolic plasticity and sensitizes breast cancer to oxidative stress},
journal = {Apoptosis},
year = {2026},
volume = {31},
number = {12},
doi = {10.1007/s10495-026-02471-3}
}
EUVIMED